Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Ali Ataya

Pulmonary Vascular Med · UF

View

Dr. Naftali Kaminski

Interstitial Lung Disease · Yale College

View

Dr. Auston Stiefer

Interstitial Lung Disease · CU Anschutz Medical Campus

View

Dr. Justin Zhang

Critical Care · UCLA

View

Dr. Panagis Galiatsatos

Critical Care · Johns Hopkins

View

Dr. MeiLan Han

Asthma & COPD · UMHS

View

Dr. Kevin Chung

Critical Care · SeaStar Medical

View

Dr. Diego J. Maselli

Asthma & COPD · UTHSCSA

View

Dr. Amos E. Dodi

Critical Care · MMC

View

Dr. Imre Noth

Interstitial Lung Disease · University of Virginia

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms

    Overview

    Endotypes of Vascular Health Predict Transplantation-Free Survival in Pulmonary Hypertension.

    Jul 17, 2026DOI: 10.1161/jaha.125.048795Journal ArticleAHA

    Written by: Samar FarhaBo HuRuoying ChenJohn BarnardSuzy ComhairGustavo HeresiJoseph ParambilAdriano TonelliGerald BeckErika Berman-RosenzweigHilary DuBrockJ Emanuel FinetRobert P FrantzGabriele GrunigPaul M HassounAnna R HemnesNicholas HillEvelyn HornChristine JellisJane A LeopoldMargaret M ParkFranz P RischardCatherine SimpsonW H Wilson TangMitchell A OlmanSerpil C ErzurumRaed A DweikPVDOMICS Study Group

    Find these authors on Roon

    AH
    Dr. Anna Hemnes
    Pulmonary Vascular Med · Vanderbilt

    Summary

    BACKGROUND: The current classification of pulmonary hypertension (PH), based largely on expert opinion, has limitations in prognostication and guiding therapies. We hypothesize that novel PH clusters that predict survival will reveal mechanistic phenotypes associated with biomarkers of vascular health across all PH groups.METHODS: We first identify novel PH clinical clusters by performing unsupervised clustering analysis on the CC-PH (Cleveland Clinic PH) registry (N=1529). We develop classification models to predict the new PH clusters and then apply them to the multicenter PVDOMICS (Pulmonary Vascular Diseases Phenomics) cohort (N=853) for validation. We compare transplantation-free survival across the new PH clusters. We quantify metabolites of the arginine-nitric oxide pathway and D-dimer levels and calculate global arginine bioavailability (arginine/[ornithine+citrulline]) to assess endothelial function and activation in the new clusters and link these biomarkers to clinical outcomes.RESULTS: Clustering analysis identify 3 clear clusters in CC-PH that are validated in PVDOMICS and outperform conventional classifications in predicting transplantation-free survival. The phenotype associated with the worst survival is characterized by reduced lung diffusion capacity, decreased arginine bioavailability and nitrate levels, and elevated D-dimer levels, consistent with loss of pulmonary microcirculation and endothelial dysfunction.CONCLUSIONS: We identify new informative PH phenotypes associated with mortality and defined by biomarkers of endothelial function and activation. Loss of endothelial health and pronounced pulmonary vascular rarefication contribute more substantially to mortality across the spectrum of PH than right heart function. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02980887.
    AHDr. Anna Hemnes

    Dr. Anna Hemnes

    Pulmonology & Critical Care · Pulmonary Vascular Medicine
    Vanderbilt Health
    annahemnes